
- Adult sleep need
- 7 or more hours a night (CDC)
- Sermorelin
- Raises growth hormone; sleep benefit evidence is small and short-term
- DSIP
- Not FDA-approved; advisory committee voted against it in July 2026
- NAD+
- Raises NAD+ levels; energy benefit unclear in human studies
Energy is mostly built overnight
Caffeine and stimulants borrow energy against later fatigue. Lasting energy depends on enough sleep, of good enough quality, at consistent times. The CDC notes that adults 18 to 60 need 7 or more hours, and that too little sleep is linked to poorer mood, weight gain, heart and metabolic problems, and reduced attention and memory.
That's why a peptide that claims to give you energy without fixing sleep is unlikely to deliver. The more useful question is what's disrupting your sleep or draining your energy in the first place.
What's offered, and the evidence for each
- Sermorelin: prompts the pituitary to release growth hormone, much of which is normally released during deep sleep. Small studies suggest possible effects on sleep, but evidence in healthy midlife adults is limited, and the dissolving tablet form hasn't been tested in published controlled trials.
- DSIP (delta sleep-inducing peptide, or emideltide): first described in animal sleep research in the 1970s, with inconsistent results. It isn't FDA-approved, and how it acts in the human brain remains unclear.
- NAD+: a coenzyme involved in cellular energy. A 2023 review found that raising NAD+ with supplements is safe and achievable, but whether it improves physiological function is unclear.
What happened with DSIP in 2026
DSIP was previously in the FDA's Category 2 for compounding substances with significant safety concerns. Its nomination was withdrawn in April 2026. In July 2026, the FDA's Pharmacy Compounding Advisory Committee considered it for opioid withdrawal, chronic insomnia and narcolepsy and voted narrowly against recommending it for the 503A bulks list. FDA staff had said the evidence was insufficient, the peptide wasn't adequately characterized and approved therapies already exist.
If prescribed anywhere, DSIP would be a compounded product that isn't FDA-approved and hasn't been reviewed by the FDA for safety, effectiveness or quality.
Often a hormone or health story
- Perimenopause and menopause: night sweats and hormonal shifts commonly break up sleep. The Menopause Society lists better sleep among the benefits of hormone therapy when hot flashes are the cause.
- Low testosterone in men can contribute to fatigue and low drive.
- Sleep apnea: loud snoring, gasping and daytime sleepiness are classic signs. The NHLBI notes it raises the risk of stroke and heart attack and is diagnosed with a sleep study.
- Low iron, an underactive thyroid and high blood sugar all cause fatigue and are easy to test.
- Alcohol, late caffeine, shift work, depression and some medicines also disrupt sleep.
Sleep habits still do the heavy lifting
- Keep the same bedtime and wake time every day, including weekends.
- Keep the bedroom quiet, dark and cool.
- Turn off screens at least 30 minutes before bed.
- Avoid caffeine in the afternoon and evening, and large meals or alcohol close to bedtime.
- Get regular exercise, ideally not right before bed.
- For long-term insomnia, cognitive behavioral therapy for insomnia (CBT-I) is usually the first recommended treatment.
The cost of running on borrowed energy
Many people in midlife have adapted to chronic under-sleeping with extra coffee, a late-afternoon snack and a glass of wine to wind down. Each step makes the next night's sleep a little worse. Over months, that pattern can look like a hormone problem or burnout.
Breaking the cycle often starts with one change, such as a fixed wake time or cutting alcohol on weeknights, and tracking how you feel for two weeks. That baseline also makes it easier to judge any treatment you add later.
Track before you treat
For two weeks, note bedtime, wake time, night wakings, caffeine and alcohol, and rate your energy at mid-afternoon. Patterns often jump out: wine on three nights and worse sleep on the same three nights, or waking at 3 a.m. with night sweats.
Bring that log to your visit. It helps your clinician pick the right next step and gives you a baseline to judge any treatment against.
How HealifyMD approaches sleep and energy
Your clinician asks about your sleep pattern, snoring, night sweats, alcohol, mood and medicines, and may suggest labs, priced separately, or a sleep study referral. Treatment might be hormone therapy, testosterone evaluation, a sleep apnea workup or a peptide trial with clear expectations. Listed prices include sermorelin ODT from $199/month, NAD+ injection from $199/month and DSIP from $200/month, all compounded and confirmed at your eligibility review.
Common questions
Are peptides like a stronger cup of coffee?
No. They aren't stimulants, and any effects on energy, if they occur, build gradually and depend on better sleep or metabolism.
Which peptides are discussed for sleep?
Sermorelin and DSIP most often, with NAD+ discussed for energy. Evidence for all three in healthy adults is limited.
Is DSIP FDA-approved?
No. An FDA advisory committee voted against recommending it for the compounding bulks list in July 2026.
Could my low energy be hormonal?
Yes, often. Perimenopause, menopause and low testosterone commonly affect sleep and energy, and they're treatable.
Should I be checked for sleep apnea?
If you snore loudly, gasp at night or are very sleepy during the day, ask about a sleep study. Untreated sleep apnea affects energy, mood and heart health.
Do peptides replace good sleep habits?
No. Consistent sleep timing, a cool dark room and limiting alcohol and late caffeine have stronger evidence.
Are these peptides safe?
Long-term safety data are limited for DSIP and for injected NAD+. Your clinician will review your health and medicines before any prescription.
Sources
We cite government agencies, professional societies and peer-reviewed research. See our editorial policy.
- About SleepCenters for Disease Control and Prevention
- Sleep ApneaNational Heart, Lung, and Blood Institute
- July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration
- FDA advisory committee backs two more peptides, rejects one for compounding listRegulatory Affairs Professionals Society
- Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions (2023)The Journals of Gerontology: Series A (via University of Delaware)
- Hormone TherapyThe Menopause Society